The stress response during chronic conditions increases vulnerability to diseases through the activation of adaptive
systems, in particular, the hypothalamus-pituitary-adrenal (HPA) axis. Dysregulation in HPA activity (central and peripheral)
has been reported in chronic diseases, like metabolic syndrome, type-2 diabetes mellitus, atherosclerosis-related
disease, essential hypertension, dementia, depression, particularly during comorbid conditions.
Different targets of anti-glucocorticoid treatment have been proposed, acting at supra-hypothalamic, HPA axis, glucocorticoid
receptor and post-receptor levels. The recent promising patents on the therapy against glucocorticoid-mediated
damage will be presented and discussed.